George Grunberger1. 1. Grunberger Diabetes Institute, 43494 Woodward Avenue, suite 208, Bloomfield Hills, MI, 48302, USA, grunberger@gdi-pc.com.
Abstract
PURPOSE: To review efficacy and safety data of dipeptidyl peptidase-4 inhibitors used in treatment of patients with type 2 diabetes mellitus. METHODS: A search of MEDLINE®/PubMed®, a service of the National Library of Medicine of the National Institutes of Health as well as of the original publications of individual trials with dipeptidyl peptidase-4 inhibitors was carried out. RESULTS: Dipeptidyl peptidase-4 inhibitors are orally administered medications indicated for improved glycemic control in patients with type 2 diabetes. They inhibit activity of the enzyme dipeptidyl peptidase-4 responsible for inactivating nutrient-released incretin hormones (mainly glucagon-like peptide-1 and glucose-dependent insulinotropic peptide). As a result, the effect of the incretin hormones is enhanced, leading to improved β-cell function and inhibition of the glucagon secretion from the pancreatic islets. Patients can expect to see lowering of fasting and postprandial glucose levels (by 0.5-1 mmol/l and 2-3 mmol/l, respectively), leading to reduction of hemoglobin A1c by 0.5-0.9% (depending on the baseline hemoglobin A1c). CONCLUSION: Dipeptidyl peptidase-4 inhibitors are generally well tolerated, with minimal risks of hypoglycemia or weight gain. Many postmarketing and surveillance studies are now conducted which focus on long-term safety and cardiovascular outcomes.
PURPOSE: To review efficacy and safety data of dipeptidyl peptidase-4 inhibitors used in treatment of patients with type 2 diabetes mellitus. METHODS: A search of MEDLINE®/PubMed®, a service of the National Library of Medicine of the National Institutes of Health as well as of the original publications of individual trials with dipeptidyl peptidase-4 inhibitors was carried out. RESULTS:Dipeptidyl peptidase-4 inhibitors are orally administered medications indicated for improved glycemic control in patients with type 2 diabetes. They inhibit activity of the enzyme dipeptidyl peptidase-4 responsible for inactivating nutrient-released incretin hormones (mainly glucagon-like peptide-1 and glucose-dependent insulinotropic peptide). As a result, the effect of the incretin hormones is enhanced, leading to improved β-cell function and inhibition of the glucagon secretion from the pancreatic islets. Patients can expect to see lowering of fasting and postprandial glucose levels (by 0.5-1 mmol/l and 2-3 mmol/l, respectively), leading to reduction of hemoglobin A1c by 0.5-0.9% (depending on the baseline hemoglobin A1c). CONCLUSION:Dipeptidyl peptidase-4 inhibitors are generally well tolerated, with minimal risks of hypoglycemia or weight gain. Many postmarketing and surveillance studies are now conducted which focus on long-term safety and cardiovascular outcomes.
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Baptist Gallwitz; Julio Rosenstock; Thomas Rauch; Sudipta Bhattacharya; Sanjay Patel; Maximilian von Eynatten; Klaus A Dugi; Hans-Juergen Woerle Journal: Lancet Date: 2012-06-28 Impact factor: 79.321
Authors: F J Lavalle-González; A Januszewicz; J Davidson; C Tong; R Qiu; W Canovatchel; G Meininger Journal: Diabetologia Date: 2013-09-13 Impact factor: 10.122
Authors: Ralph A DeFronzo; Miguel N Hissa; Alan J Garber; Jorge Luiz Gross; Raina Yuyan Duan; Shoba Ravichandran; Roland S Chen Journal: Diabetes Care Date: 2009-05-28 Impact factor: 19.112